One of the most novel approaches in diabetes research is the gene therapy developed by Kriya Therapeutics, which involves introducing the insulin and glucokinase genes directly into skeletal muscle.
The idea is that, after a single intramuscular injection, the muscle cells themselves learn to help regulate blood glucose levels, complementing or reducing the need for external insulin.
The first human clinical trial with this technology is expected to begin during 2026, a step considered key to evaluating its real safety and efficacy in people with diabetes.